ANKUR
DRUGS AND PHARMA LTD

Regd. Off.:
20th Floor, Lotus Business Park,
Off. Andheri Link Road,
Andheri (West), Mumbai - 400 053.

UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31ST DECEMBER, 2010

(Rs. lacs)

Sr. No.	PARTICULARS	**Quarter ended on 31.12.2010 (Unaudited)**	Quarter ended on 31.12.2009 (Unaudited)	**Nine Months ended on 31.12.2010 (Unaudited)**	Nine Months ended on 31.12.2009 (Unaudited)	**Year ended on 31.03.2010 (Audited)**
1	Net Sales/Income from Operations	**15,018.52**	26,040.16	**70,275.81**	80,610.44	**106,740.76**
2	Other Income	**21.63**	42.68	**61.90**	118.20	**198.98**
3	Total Income	**15,040.15**	26,082.84	**70,337.71**	80,728.64	**106,939.74**
4	Total Expenditure					
	a) (Increase)/decrease in stock	**49.12**	(30.71)	**(668.49)**	3,389.84	**(372.26)**
	b) Materials Consumed	**10,662.78**	19,249.16	**50,971.80**	56,848.41	**79,950.60**
	c) Labour and Staff Cost	**858.31**	519.67	**2,133.83**	1,495.41	**2,322.73**
	d) Manufacturing, administrative & selling expenses	**1,276.61**	862.44	**3,846.33**	2,950.67	**3,620.46**
5	PROFIT BEFORE DEPRECIATION, FINANCE COST AND TAX	**2,193.33**	5,482.28	**14,054.24**	16,044.31	**21,418.21**
6	Depreciation	**1,925.13**	598.69	**3,894.22**	1,776.53	**2,663.98**
7	PROFIT BEFORE FINANCE COST, EXCHANGE FLUCTUATION AND TAX	**268.20**	4,883.59	**10,160.02**	14,267.78	**18,754.23**
8	a) Interest and Financial Charges	**2,522.64**	1,901.23	**7,603.75**	5,745.41	**8,074.98**
	b) Provision for Exchange difference on Foreign Currency Loans	**-**	(419.71)	**-**	(1,381.84)	**(1,543.07)**
	c) Provision for redemption on redemption of FCCBs	**227.45**	(235.90)	**679.88**	185.48	**343.72**
9	PROFIT BEFORE EXCEPTIONAL ITEM AND TAX	**(2,481.89)**	3,637.97	**1,876.39**	9,718.73	**11,878.60**
10	Add/(Less): Exceptional Item: Provision for Dimniution in value of Investments	**-**	(57.92)	**(76.01)**	(133.93)	**(121.43)**
11	PROFIT BEFORE TAX	**(2,481.89)**	3,695.89	**1,952.40**	9,852.66	**12,000.03**
12	Provision for taxation					
	- Current Tax	**(473.00)**	629.00	**390.00**	1,675.00	**1,705.36**
	- Deferred tax/(assets)	**-**	250.00	**-**	400.00	**1,201.40**
	- Excess provision for Income-tax for earlier year		3.00		-	**475.51**
13	Net profit after tax (11-12)	**(2,008.89)**	2,813.89	**1,562.40**	7,777.66	**8,617.76**
14	Paid-up Equity Share Capital	**1,934.16**	1,934.16	**1,934.16**	1,934.16	**1,934.16**
15	Reserves & Surplus (Excluding Revaluation Reserve)	**-**	-	**-**	-	**33,794.03**
16	Earning per share (Rs.)					
	- Basic	**(10.39)**	14.55	**8.08**	40.21	**44.56**
	- Diluted	**(8.07)**	10.47	**6.27**	32.35	**30.33**
17	Aggregate of Non-Promoter Shareholding					
	- Number of Shares	**14,884,059**	12,226,146	**14,884,059**	12,226,146	**12,221,110**
	- Percentage of Shareholding (%)	**76.95**	63.21	**76.95**	63.21	**63.19**
18	Promoter and Promoter Goup Shareholding					
	a) Pledged/ Encumbered					
	- Number of Shares	**3,473,500**	2,972,750	**3,473,500**	2,972,750	**3,683,000**
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	**77.92**	41.75	**77.92**	41.75	**51.72**
	- Percentage of Shares (as a % of the total share capital ofthe company)	**17.96**	15.37	**17.96**	15.37	**19.04**
	b) Non-encumbered					
	- Number of Shares	**984,031**	4,148,144	**984,031**	4,148,144	**3,437,480**
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	**22.08**	58.25	**22.08**	58.25	**48.28**
	- Percentage of Shares (as a % of the total share capital of the company)	**5.09**	21.45	**5.09**	21.45	**17.77**

NOTES :

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors of the company in their meeting held on 14th February, 2011.
2. During the year, the company has not provided foreign Exchange Loss/(Gains) on account of exchange differences arising during the period(s) on foreign currency borrowings including Foreign Currency Convertible Bonds. The same will be accounted for at the end of the financial year.
3. The Company has commercially launched Fentanyl, Decongestion patch and ondensetron rapid film besides inhouse developed Mosquito repellent patch under Brand Name of FENTAGESIC, COLD FLEECE, EMISHUN AND MOSFUSE respectively.
4. The Company has set-up STATE OF THE ART facilities at Baddi (H.P.). On Account of highly technological advanced facilities set up, the cost of project has gone up which was not factored. In absence of financial closure of the project the company is facing liquidity concerns. The company has therefore made a reference to CDR for restructuring the existing debt and also sanction of fresh facilities on softer terms without any waiver / write off.
5. Investor complaints received and disposed off during quarter ended 31st December, 2010 :

Complaints pending at the beginning of the quarter	3
Complaints received during the quarter	5
Disposal of complaints	8
Complaints lying unresolved at the end of the quarter	Nil

6. As the company operates in a single business segment viz: "Pharmaceuticals Formulations", in the context of Accounting Standard 17, disclosure of segment information is not applicable.

For ANKUR DRUGS AND PHARMA LIMITED

Sd/-
PURNANDU JAIN
Chairman & Managing Director

Place : Mumbai.
Dated : 14th February, 2011.